[ad_1]
Whereas the headline determine of a A$1.6 billion sale value for Eucalyptus was a trigger for celebration, seen by many an vital payday for an Australian startup sector the place liquidity is a matter, the positive print of the deal reveals there’s an extended option to go earlier than the money trickles right down to buyers and shareholding staff.
The web healthcare startup, based in 2019, had been trying to elevate new funding at a valuation that may have minted it as a unicorn when the US$1.15 billion take care of NYSE-listed rival Hims and Hers dropped.
The acquisition value is round 10x of the US$111 million in venvture funding the startup raised over 4 years. Eucalyptus final raised $50m at a $520m valuation in April 2023.
It’s a daring marriage by either side, banking that the entire shall be higher than the sum of their rival components.
Shares in San Francisco-based Hims & Hers Well being have tanked 64% over the past 12 months, together with a 55%+ slide within the first two months of 2026 – an 8% fall within the days because the deal was introduced.
The well being and wellness platform isn’t any Robinson Crusoe in falling out of favour with buyers – Nasdaq-listed office software program agency Atlassian’s shares have plunged greater than 70% in 12 months and greater than 50% in 2026 as software program corporations normally wrestle amid the AI transformation.
However Hims & Hers, based in late 2017, earlier than itemizing on the NYSE in January 2021 by way of a particular goal acquisition firm (SPAC), will not be a software program firm per se. Like Eucalyptus, it sells on-line consultations and coverings for well being points similar to weight reduction, sexual dysfunction, hair loss, skincare and psychological well being.
Authorized and regulatory troubles
A part of the issue is a bitter battle with Novo Nordisk, producer of GLP-1 weight reduction medicine Ozempic and Wegovy.
Hims & Hers signed a take care of the Danish drugmaker in April 2025 to promote Wegovy. It lasted about three months earlier than Novo Nordisk ripped it up, claiming their buyer was promoting Wegovy copies illegally, in addition to objecting to the advertising techniques of the US startup.
The dispute escalated final month when Novo Nordisk launched US authorized motion, suing Hims & Hers for damages over promoting compounded variations of its medicine, claiming they infringe on the Danish firm’s patents, in addition to asking the courtroom to ban their sale.
It’s a pincer motion, because the US Drug and Meals Administration can be gunning for Hims & Hers over its advertising and compounded medicine, saying its personal investigation and crackdown just a few weeks in the past.
By the way, Eucalyptus has some inkling of what’s happening having pursued the same path just a few years again earlier than compounding weight reduction medicine had been banned by the federal authorities in early 2024, amid objections from the startup.
In the meantime, Hims & Hers (NYSE: HIMS) shares now sit round US$14.50, down from a 12-month excessive of $70.43, for a market cap simply above US$3.3 billion.
Meaning Eucalyptus is now price round a 3rd of acquirer’s present market cap.
However none of this battle – an existential risk to Hims & Hers – prevented breathy reporting by some information websites of how 100 staff within the Eucalyptus ESOP shall be millionaires, whereas VCs “stand to make a motza”, particularly Blackbird’s 2018 fund delivering a 34.5x return “as soon as paid out”.
That’s an vital qualifier within the reporting, as a result of there are loads of devils within the particulars of this M&A deal.
Excessive bars to clear
Numerous work to be achieved by the Eucalyptus workforce to attain the whole acquisition value.
Blackbird owns round 1 / 4 of Sydney startup, having invested seven instances. So theoretically, they’re sitting on one thing circa a A$400m return.
Associate Nick Crocker instructed Capital Temporary that: “the transaction will see greater than 2x our total 2018 fund returned over the approaching years”.
However the A$1.6bn headline determine continues to be a great distance from the fact for a lot of shareholders. Persistence can be required, since it is going to be FY2029 earlier than the whole acquisition value is finalised.
First up, if and when it goes by way of in mid-2026 – Eucalyptus operates in a number of areas throughout Europe, Asia and North America, so the deal is probably going topic to multi-jurisdictional regulatory clearances – Hims & Hers is making an preliminary 40% downpayment in money: US$240m (c. A$340m), cut up between employees and buyers, the previous getting slightly over half that determine, US$133m.
One other US$710m is paid out to non-staff, post-close, over 18 months.
Solely key worker sellers rating the 40% of their entitlement upfront – the remaining 60% relies on earnouts, price as much as US$200m, and tied to income/EBITDA targets over three years, spanning 2026-28.
Meaning staff are in golden handcuffs till then if they need the upside. There’s US$50m in HIMS shares on the desk underneath the corporate’s 2020 Fairness Incentive Plan – $12.5m a 12 months over 4 years – “to sure staff” who be a part of the US firm from Eucalyptus.
Sure it’s a wise retention mechanism to maintain key employees to assist guarantee the continued success of Eucalyptus, however stroll away earlier than then and people staff possible forfeit a big slice of their payout.
What buyers get
Buyers initially rating round 18 cents within the $1 – 20% of 90% of their entitlement upfront when the deal closes. Then they’re paid the remaining 70% six instances, each three months, over the subsequent 18 months.
So by across the finish of 2027, buyers in funds similar to Blackbird, Airtree, Woolworths VC fund W23, OneVentures, Athletic Ventures, and Mary Meeker’s BOND Capital ought to have a reasonably clear concept of how they’ve achieved, together with the ultimate 10% of investor returns tied to the efficiency targets.
On high of all that, then the US$1.15 billion sale value can be topic to web debt and dealing capital changes.
Its final filed accounts, in FY2024, Eucalyptus had income of $120.9 million, a rise of $41m on the earlier 12 months, whereas chopping its after-tax losses by greater than half to $15.2m.
Given the enterprise was nonetheless almost definitely working at a loss and burning money – therefore elevate plans ( it was rumoured to have secured $190m in VC funding at a A$1.37bn valuation final November) – the changes might additionally scale back the deal dimension.
It will get higher, as a result of Hims & Hers has, at “its sole discretion”, is in a position pay as much as 60% of deferred and earnout funds in HIMS inventory reasonably than money. The value shall be set by a VWAP at time of issuance, not when the deal was lower in mid February, so if issues go badly within the courts and HIMS inventory drops additional between now and cost, Eucalyptus stockholders are shortchanged on the deal, whereas additionally being uncovered to HIMS fairness danger and not using a hedge.
M&A is a difficult win
To grasp the danger right here, you have to take a look at the info round M&A offers. Greater than half (50–70%) are thought of failures by way of metrics similar to shareholder worth, post-merger efficiency and value synergies (advising on one is profitable, nevertheless, for the consultants concerned).
Evaluations by Harvard Enterprise Evaluate and others concluded that round 30–50% of M&A offers create worth for the buying firm’s shareholders, whereas usually, many see the share value fall. A majority of acquirers overpay and underdeliver on synergies (hiya to the Ellisons, homeowners of Paramount, and congrats on the Warner Bros deal).
Sure, a majority of shareholders within the firm being acquired rating a premium, but when it’s being paid within the acquirer’s inventory, then its a problem to win once you’re on either side of the commerce.
Only a fast reminder of how powerful mergers may be.
In 2021, Simply Eat Takeaway (JET) – the UK firm that shut down Menulog in Australia final 12 months – purchased US rival Grubhub for US$7.3 billion. Lower than 4 years later, in late 2024, JET offloaded the enterprise for US$650m – a $6.5bn loss. JET itself was taken over for US$4.2bn 12 months in the past.
And Australian startup Sendle, which merged with two comparable US supply companies in mid-2025, is now in liquidation, having ceased buying and selling in January because the post-merger.
And who can overlook Rupert Murdoch shopping for MySpace 20 years in the past for US$580 million, then promoting it for $35m.
After all, everybody has fingers crossed that the Eucalyptus deal is a roaring success and a shot within the arm for Australian startups and buyers having been pining for amid an absence of liquidity occasions as a number of VC funds attain the tip of their 10-year lifespans.
However first up, it’s all fingers in founder mode for the Eucalyptus workforce to earn what they’ve labored the previous seven years for.
[ad_2]
Supply hyperlink